Hukyndra

Hukyndra is a prescription medication that contains the active ingredient adalimumab, delivered as a subcutaneous injection. It is classified as a TNF‑alpha inhibitor and immunomodulator, marketed in the European Union. The product’s strength and dosage form are not specified in the available data. Hukyndra is used to modulate immune activity in several chronic inflammatory disorders. It is administered under the supervision of a healthcare professional and requires a prescription.

Hukyndra is indicated for several autoimmune and inflammatory conditions where TNF‑alpha plays a key role.

- Rheumatoid arthritis in adults. - Psoriatic arthritis and related joint disease. - Ankylosing spondylitis, a form of axial spondyloarthritis. - Moderate to severe plaque psoriasis. - Crohn’s disease and ulcerative colitis when other therapies are insufficient. - Hidradenitis suppurativa that is refractory to conventional treatment.

Adalimumab may cause a range of adverse reactions, most of which are mild to moderate, while rare events can be serious.

Common: - Injection site pain, redness, or swelling. - Upper respiratory tract infections (e.g., nasopharyngitis). - Headache. - Mild rash or itching.

Serious: - Serious infections such as tuberculosis, bacterial sepsis, or fungal infections. - Reactivation of hepatitis B virus. - Development of malignancies, including lymphoma or skin cancer. - Severe allergic reactions, including anaphylaxis or angioedema.

Before starting Hukyndra, healthcare providers assess several safety considerations to minimize risks associated with immunosuppression.

- Screen for latent tuberculosis and treat before initiating therapy. - Evaluate for active infections; postpone treatment if serious infection is present. - Assess hepatitis B status and monitor during therapy. - Use caution in patients with a history of malignancy. - Monitor for signs of demyelinating disease or neurological symptoms. - Discuss pregnancy and breastfeeding plans, as safety data are limited.

Adalimumab can interact with other medicines, affecting infection risk or immune response, so review concomitant drugs carefully.

Avoid: - Live‑attenuated vaccines (e.g., measles, varicella) during treatment. - Concurrent use of other biologic immunosuppressants (e.g., abatacept, rituximab) without specialist guidance.

Use with caution: - Systemic corticosteroids, which may increase infection risk. - Immunomodulators such as methotrexate or azathioprine. - Antifungal agents that require immune competence. - Drugs that affect hepatic metabolism are generally not a concern, but monitor liver function if indicated.